We have recently identified nc886 (pre-miR-886 or vtRNA2-1) as a novel type of non-coding RNA that inhibits activation of protein kinase R (PKR). PKR's pro-apoptotic role through eukaryotic initiation factor 2 a (eIF2a) phosphorylation is well established in the host defense against viral infection. Paradoxically, some cancer patients have elevated PKR activity; however, its cause and consequence are not understood. Initially, we evaluated the expression of nc886, PKR and eIF2a in non-malignant cholangiocyte and cholangiocarcinoma (CCA) cells. nc886 is repressed in CCA cells and this repression is the cause of PKR's activation therein. nc886 alone is necessary and sufficient for suppression of PKR via direct physical interaction. Consistently, artificial suppression of nc886 in cholangiocyte cells activates the canonical PKR/eIF2a cell death pathway, suggesting a potential significance of the nc886 suppression and the consequent PKR activation in eliminating pre-malignant cells during tumorigenesis. In comparison, active PKR in CCA cells does not induce phospho-eIF2a nor apoptosis, but promotes the pro-survival nuclear factor-kB pathway. Thus, PKR has a dual life or death role during tumorigenesis. Similarly to the CCA cell lines, nc886 tends to be decreased but PKR tends to be activated in our clinical samples from CCA patients. Collectively from our data, we propose a tumor surveillance model for nc886's role in the PKR pathway during tumorigenesis.
INTRODUCTION
We have recently characterized a novel type of non-coding RNA, nc886 (pre-miR-886 or vtRNA2-1). 1 As its aliases indicate, it was originally known as a precursor microRNA 2 or as an RNA component of the vault complex. 3, 4 However, we have shown that it is neither a precursor microRNA nor a vtRNA; 1 so we have renamed it nc886 (non-coding RNA-886) and this term will be used throughout this paper and in the future. A brief summary of nc886 is: (1) its expression is ubiquitous in non-malignant human tissues but suppressed in a wide range of cancer cells, and (2) its artificial suppression leads to the activation of protein kinase R (PKR) and impaired cell proliferation. 1, 5 Recently, nc886's significance in the biology and the prognosis of acute myeloid leukemia has been reported. 6 PKR is an interferon-inducible and double-stranded RNA (dsRNA)-dependent kinase, whose role has been well established in the host defense against viral infection. In the canonical PKR pathway (reviewed in Garcia et al. 7 ), virus-derived dsRNA binds to PKR and mediates its autophosphorylation. Phosphorylated PKR (P-PKR) is an active kinase that phosphorylates eukaryotic initiation factor 2a (eIF2a subunit) at Ser51. Phosphorylated eIF2a (P-eIF2a) blocks global protein synthesis by preventing its efficient recycling by the guanine nucleotide exchange factor eukaryotic translation initiation factor 2B (eIF2B), and subsequently leads to cell death. [8] [9] [10] PKR also has the dual role of activating the nuclear factor (NF)-kB pathway, which promotes cell proliferation (reviewed in Prasad et al. 11 ). In addition to its established role in the interferon response, PKR is involved in many pathways and exerts various functions on cell growth independently of viral infection (reviewed in Mounir and Koromilas 12 ). Thus, not surprisingly, PKR is implicated in tumorigenesis. However, PKR's exact role in cancer biology remains controversial. Initially, PKR was thought to be a tumor suppressor. Early studies indicated that malignant transformation was induced by dominant-negative mutants of PKR (and thus its loss of function). PKR's pro-apoptotic role (reviewed in Gil and Esteban 13 ) was also in agreement with the notion that it is a tumor suppressor. In addition, it has been reported that PKR was suppressed or inactivated in some malignancies. [14] [15] [16] [17] [18] However, several observations have challenged the proposed role of PKR as a tumor suppressor. In some cancers, PKR and its downstream target eIF2a are induced in expression and activity.
PKR role in cancer biology. In this model, decrease of nc886 during early stages of tumorigenesis activates the classical PKR/eIF2a pathway, which leads to cell death and eliminates most precancerous and/or cancerous cells. Cancer cells that have survived must have developed bypass mechanisms to proliferate in the presence of elevated P-PKR and P-eIF2a. Once cancer cells have overcome the PKR/eIF2a cell death pathway, P-PKR could have the pro-proliferative role necessary for further tumor progression through its downstream NF-kB pathway.
In this paper, we have investigated our tumor surveillance model in cholangiocarcinoma (CCA), a cancer from the hepatobiliary epithelium. This study is the first step to elucidate the roles of nc886/PKR in cell death/proliferation during tumorigenesis.
RESULTS
Expression of nc886, PKR and eIF2a in cholangiocyte and CCA cells We measured nc886 in a battery of bile duct cells (Table 1) . Like other non-malignant human cells in our previous studies, 1 nc886 was expressed in immortalized but not malignant cholangiocyte MMNK1 cells (Figure 1 ). nc886 was also expressed in three CCA cells (M156, M214 and M055), whereas it was not expressed in M213, its derivative lines M213L0H and M213L5H, and M139 cells. For comparison, all of the bile duct cells constitutively expressed vtRNA1-1, a canonical vtRNA ( Figure 1 ).
Although PKR was constitutively expressed in cholangiocyte and CCA cells (total PKR in Figure 1 ), it was activated in all the CCA cells except for M156, as indicated by P-PKR western blot ( Figure 1 ). Similarly to P-PKR, P-eIF2a was elevated in all the CCA cell lines, but again not in the non-malignant MMNK1 (Figure 1 ). In our experiments in Figure 1 , it should be noted that all assays were performed in normally growing conditions without exposure to dsRNA, a natural activator of PKR that leads to apoptosis.
In general, CCA cells tended to have decreased nc886 but elevated P-PKR/P-eIF2a relative to non-malignant MMNK1 cells ( Figure 1 and Table 1 ). Certainly, there were exceptional cell lines; nc886 was not silenced in all the CCA cells, and nc886 was coexpressed with P-PKR in M214 and M055 cells. This is explained by the genetic diversity of CCA cells. PKR has been known to be regulated by a number of intra-/extra-cellular factors besides dsRNA (reviewed in Garcia et al. 7 ). For example, natural PKR regulators such as PACT or p58IPK may have contributed to the activation of PKR in M214 and M055 cells. We speculate that nc886 is also under complex regulation, as a number of transcription factors including the GATA family, CdxA, and MZF1 are predicted to bind to the vicinity of the nc886 locus.
Taken together with our previous result that suppression of nc886 activates PKR to P-PKR, 1 the anti-correlation between nc886 and P-PKR in a battery of cholangiocyte/CCA cells ( Figure 1 ) was intriguing and raised these questions: (1) is the expression of nc886, P-PKR and P-eIF2a related causally during tumorigenesis? and (2) how do CCA cells overcome P-PKR/P-eIF2a's apoptotic effect and proliferate? We addressed these issues in the following experiments. As we used several cell lines with different Table 1 . Cell lines used in this study
Cell line
Histological type Reference Summarized from Figure 1 nc886 PKR P-PKR eIF2a P-eIF2a
Metastatic clone from KKU-M213 Personal communication with
Abbreviations: eIF2a, eukaryotic initiation factor 2 a; P-eIF2a, phosphorylated eIF2a; PKR, protein kinase R (RNA-activated); P-PKR, phosphorylated PKR. KKU-M213L0H and KKU-M213L5H are subclones from KKU-M213, with low and high Lewis-a expression respectively (personal communication with Dr Sopit Wongkham at Khon Kaen University). expression of nc886, P-PKR and P-eIF2a, we designated their expression by þ / À signs in a parenthesis, for easy reading. For example, MMNK1 cells are (nc886 þ , P-PKR À and P-eIF2a À ; see also Table 1 ).
Causal relationship between nc886 and P-PKR A number of papers have reported PKR activation in malignancies; however, most of them did not elucidate a mechanism for that activation. In one report, 20 a PKR inhibitor protein p58IPK 35 was suggested to be the cause, because p58IPK was decreased in breast cancer cells whereas PKR was activated. However, this observation was not reproducible in other papers, and thus p58IPK's universal involvement in PKR regulation seemed unlikely. 19, 22 In this study, we found that the expression of p58IPK was consistent among the cell lines (Figure 2a) , and therefore ruled out its role in PKR regulation in CCA.
Based on our data in Figure 1 and our previous study, 1 we hypothesized that suppression of nc886 activated PKR in CCA cells. To investigate the nc886 À PKR relationship, we suppressed nc886 by transfecting antisense oligonucleotides (anti-oligos) into MMNK1, M156 and M214 cells (all nc886 þ cells) and then measured P-PKR. Compared with an anti-oligo against vtRNA1-1 ('anti-vt21_2') as a negative control, antioligos against nc886 ('anti-886s') successfully negated nc886 and induced P-PKR in all the three cell lines examined (Figures  2b-d) . Interestingly, there were two distinct mechanisms for anti-oligos to induce P-PKR. In the case of non-malignant Figure 1 . The expression profile of nc886, P-PKR and P-eIF2a from Figure 1 is summarized and indicated on the bottom. All other descriptions are the same as in Figure 1 . (b) Northern hybridization of nc886 and western blot of indicated proteins. MMNK1 cells were harvested for sample preparation, at 48 h after two rounds of transfection (at 0 and 24 h) of each indicated anti-oligo at 50 nM. All other descriptions are the same as in Figure 1 . (c) PKR pulldown assays to measure PKR/nc886 association. M156 and M214 cells were harvested at 48 h after one round of transfection of each indicated anti-oligo at 50 nM. Cell lysates were subjected to PKR immunoprecipitation, as described in Materials and methods section. RNAs from immunoprecipitates (designated as 'IP' above the gel) and from cell lysates (designated as 'input') were subjected to RT-PCR measurement of nc886, vtRNA1-1 and b-actin mRNA. MMNK1 cells, the anti-oligos depleted nc886's intracellular level (northern blot in Figure 2b ). In M156 and M214 CCA cells, the anti-oligo interfered with nc886/PKR interaction (pull-down assay in Figure 2c ). Our cellular data were reinforced by in vitro experiments. Addition of the anti-oligo against nc886 in MMNK1 lysate (nc886 þ ) increased PKR activity, as measured by in vitro kinase assays ( Figure 2e) . Conversely, addition of in vitro transcribed synthetic nc886 in M213 lysate (nc886 À ) inhibited PKR activity ( Figure 2f ). We also showed their direct physical interaction by electrophoretic mobility shift assays (EMSAs) with synthetic nc886 and purified PKR from Escherichia coli (E. coli) (Figure 2g) .
Collectively, our data demonstrated that nc886 alone is necessary and sufficient for suppression of PKR through direct physical interaction. nc886 keeps PKR repressed in MMNK1 cells, and PKR is released from that repression when nc886 is suppressed in CCA cells. However, nc886 levels could not explain P-PKR in all the CCA cells, for example, in M214 and M055 (nc886 þ , P-PKR þ ). As mentioned earlier, their intrinsic level of P-PKR could have been activated by a factor other than nc886 or p58IPK, or in these malignancies there seems to be a higher threshold level of nc886 necessary for suppression of P-PKR.
The canonical PKR/eIF2a pathway operates in MMNK1 cells but not in CCA cells One pre-requisite for our tumor surveillance model is that the canonical PKR/eIF2a pathway operates normally and leads to apoptosis in most cells, because the suppression of nc886 would eliminate such cells through this pathway. We attempted to recapitulate such a situation in non-malignant MMNK1 cells (nc886 þ , P-PKR À and P-eIF2a À ). On nc886 depletion, P-PKR phosphorylated eIF2a, decreased global protein synthesis and inhibited cell proliferation (Figures 3a and b) . Figure 2b were subjected to eIF2a western blot (upper panels) and global protein synthesis assays (lower panels). In lower panels, 10 mg of total protein was loaded onto a 10% SDS-polyacrylamide gel, and visualized by Coomassie blue staining (for total protein) and by autoradiogram (for [ nc886 represses PKR in cholangiocarcinoma N Kunkeaw et al P-PKR is known to induce apoptosis mainly through two pathways involving FADD/caspase-8 and APAF/caspase-9, both of which merge onto caspase-3 (reviewed in Garcia et al. 7 ). Consistently, we detected the active form of cleaved caspase-3 and consequent cleavage of poly(ADP-ribose) polymerase on nc886 knockdown in MMNK1 cells (lanes 1-2 in Figure 3c ). In contrast, neither caspase-3 nor poly(ADP-ribose) polymerase cleavage was seen in M156 and M214 CCA cells (lanes 3-6 in Figure 3c ), although PKR was indeed activated by nc886 depletion (Figure 2d) . Hence, there were two distinct consequences of P-PKR activity between MMNK1 cells and CCA cells. It is worth noting that M156 and M214 CCA cells were both P-eIF2a þ (Figure 1) .
To interrogate which step of the PKR pathway is abrogated in these two cell lines, we measured P-eIF2a and global protein synthesis on nc886 knockdown (Figure 3d ). In the case of M156 cells (nc886 þ , P-PKR À and P-eIF2a þ ), P-eIF2a was induced but global protein synthesis was not significantly decreased. In the other case of M214 cells (nc886 þ , P-PKR þ and P-eIF2a þ ), the induction of P-eIF2a was not seen and consistently global protein synthesis was unaffected.
So far, we have shown that the canonical PKR/eIF2a pathway operated normally in non-malignant MMNK1 cells, but not in CCA cells. Phosphorylation of eIF2a (M214) or inhibition of global protein synthesis (M156) malfunctioned so that the two CCA cells escaped from apoptosis on nc886 suppression.
The PKR pathway on introduction of dsRNA Next, we expanded our investigation to CCA cells lacking nc886. To activate the PKR/eIF2a pathway, we transfected a dsRNA mimic poly(I:C) into M139 cells (nc886 À , P-PKR þ and P-eIF2a þ ). For comparison, we included two cell lines, MMNK1 (nc886 þ , P-PKR À and P-eIF2a À ) and M214 (nc886 þ , P-PKR þ and P-eIF2a þ ) in these experiments.
Poly(I:C) activated PKR in all the cell lines tested (Figure 4a ). The intact PKR/eIF2a pathway was again confirmed in non-malignant MMNK1 cells in which poly(I:C) inhibited global protein synthesis via P-eIF2a (Figure 4a ). In contrast, P-PKR did not further phosphorylate eIF2a nor decrease global protein synthesis in M214 and M139 cell lines (Figure 4a) . In M214 cells, poly(I:C) treatment and nc886 knockdown yielded the same result (compare Figures 4a and 3d) . So, P-PKR failed to phosphorylate eIF2a in these two cells.
This raised a question as to whether P-PKR also failed to activate its other downstream events. As eIF2a and NF-kB are two representative downstream branches in the PKR pathway, we examined the NF-kB pathway (Figure 4b ). Poly(I:C) treatment activated the NF-kB pathway in all the three CCA cell lines tested, including M214 and M139 where P-PKR failed to phosphorylate eIF2a. This NF-kB activation was PKR dependent, as it was abrogated by 2-aminopurine (2-AP), a PKR inhibitor (Figure 4b) . Thus, M214 and M139 CCA cells selectively blocked the eIF2a branch, but not the NF-kB branch in the PKR pathway.
The NF-kB pathway in CCA cells As the activation of NF-kB by P-PKR was operative in the presence of dsRNA, we questioned if the intrinsic NF-kB activity was elevated in CCA cells (P-PKR þ ) relative to MMNK1 cells (P-PKR À ). First, we wanted to ensure that PKR activity was indeed higher in CCA cells than in MMNK1 cells by employing in vitro kinase assays. Consistent with our earlier P-PKR western data (Figure 1 ), M214 and M213 cells (P-PKR þ ) had a robust PKR kinase activity, compared with the very low activity of the MMNK1 cell line (P-PKR À ) (Figure 5a) . Accordingly, the NF-kB activity of these two CCA cells was higher than that of MMNK1, as assessed by luciferase assays measuring the NF-kB-responsive promoter activity (Figure 5b ) and by quantitative reverse transcriptase-PCR (qRT-PCR) measurement of NF-kB target mRNAs (Figure 5c ). The dependence of NF-kB activity on P-PKR (thus PKR's kinase activity) was reinforced by knockdown experiments. In M156 and M214 (both nc886 þ ), nc886 knockdown resulted in PKR activation in our earlier data (Figure 2d) . Consistently, NF-kB was activated, as shown by qRT-PCR of NF-kB target genes (Figure 5d ). This activation was significantly decreased by simultaneous knockdown of PKR by small interfering RNA (siRNA), demonstrating the requirement of PKR for the NF-kB activation by nc886 depletion.
Finally, we examined if the elevated PKR/NF-kB activity had a role in the proliferation of CCA cells. For this, we treated cells with caffeic acid phenethyl ester (CAPE), a chemical inhibitor for NF-kB, and measured cell proliferation. CAPE treatment suppressed proliferation of M214 and M213 (both P-PKR þ ) CCA cells (Figure 5e ), demonstrating NF-kB's pro-proliferative role therein. A similar effect of CAPE on CCA growth has been reported previously. 36 In agreement, inhibition of PKR activity by 2-AP treatment also attenuated the proliferation of these CCA cells (Figure 5f ). The elevated P-eIF2a in CCA cells The intrinsic expression of P-eIF2a in CCA cells was still intriguing but not addressed yet. An important obvious question was what caused eIF2a to be phosphorylated. The primary candidate was certainly P-PKR, an eIF2a kinase, because its expression was positively correlated with P-eIF2a ( Figure 1 ). However, this was questionable, because eIF2a was not phosphorylated by P-PKR in CCA cells on nc886 knockdown or dsRNA treatment (Figures 3 and  4) . To test this, we suppressed PKR in M214 and M213 cell lines (both P-PKR þ and P-eIF2a þ ). siRNAs against PKR successfully decreased total PKR and P-PKR, but not P-eIF2a (Figure 6a ). Thus, it is unlikely that P-eIF2a was induced by P-PKR in these cell lines.
Another candidate was MetAP2(p67), as it is known to bind eIF2 and protect eIF2a from phosphorylation by P-PKR (reviewed in Datta 37 ). We found its expression to be higher in CCA cells than in MMNK1 (Figure 6b ). These data were against our scenario that eIF2a would be released from its protection and hyperphosphorylated when MetAP2(p67) decreased in CCA. Our data suggested that P-eIF2a was induced in CCA cells by some factors other than P-PKR or MetAP2(p67).
An equally important question was how CCA cells could proliferate in the presence of P-eIF2a. Obviously, their protein translation normally occurred in spite of P-eIF2a's intrinsic expression (Figure 1 ), as well as its induction by nc886 knockdown (M156 in Figure 3d ). P-eIF2a's mechanism for inhibition of protein translation is to bind to eIF2B with an excessively high affinity and consequently deplete productive eIF2B, an essential factor for protein translation. 38 Accordingly, overexpression of eIF2B has been shown to negate P-eIF2a's inhibitory effect on protein translation. 39, 40 In addition, high expression of eIF2B in malignancies has been reported. 20, 41 We measured eIF2B-e, the catalytic subunit of the penta-peptide eIF2B complex, 42 and found it to be elevated in CCA cell lines relative to MMNK1 (Figure 6b) . Thus, it is likely that compensating high levels of eIF2B was one mechanism by which CCA cells overcame P-eIF2a. nc886 and P-PKR expression in clinical samples Thus far, we have shown the significance of nc886 in the PKR pathway in the cholangiocyte/CCA cell culture. To corroborate our in vitro findings, we measured nc886 in clinical specimens from CCA patients. Among 16 pairs of CCA tumors and adjacent normal tissues, nc886 decreased in tumor in eight cases, increased in four cases and did not change significantly in four cases (Figure 7a ). This pattern was very similar to that observed in the seven CCA cell lines (Figure 1) . Compared with MMNK1, nc886 decreased in four CCA cell lines and increased in one CCA cell line.
Next, we measured P-PKR in another set of eight CCA samples with matched normal liver tissue samples by immunohistochemistry (IHC). P-PKR was strongly expressed in CCA but not at all in surrounding fibrous tissues (Figure 7b ). In six of eight patients, the P-PKR expression in CCA was stronger than in matched bile ducts or liver tissues (Figures 7b and c) . Thus, we have provided evidence here that the nc886/P-PKR expression in CCA patients was similarly altered to that observed in the CCA cell lines (Figure 1 ). Although accumulation of more clinical data will be needed to assess nc886/P-PKR's in vivo significance more accurately, we suggest that the nc886/PKR tumor surveillance mechanism could operate in vivo.
DISCUSSION
In this report, we substantiated that a non-coding RNA, nc886, represses PKR. We have provided clear evidence that nc886 directly binds to PKR and inhibits its phosphorylation and kinase activity (Figure 2 ). Their molecular interaction has been characterized in detail. 43 The high P-PKR (thus elevated PKR activity) in CCA cells, albeit not all of them, is attributed to suppression of nc886 therein. This causal relationship is probably true also in breast cancer cells, as we found an anti-correlation between nc886 and P-PKR by comparing published data 20 to our data. 1 Our data presented here in CCA support our tumor surveillance model, which is described in the Introduction section and illustrated in Figure 8 . In non-malignant MMNK1 cells, artificial suppression of nc886 led to apoptosis through the classical PKR cell death pathway via P-eIF2a (Figure 3) . We presume that the canonical PKR/eIF2a pathway is intact in most pre-malignant cells and eliminates these cells when nc886 is suppressed during certain stages of tumorigenesis, similarly to MMNK1 cells.
However, cancer is a complex genetic disease involving an accumulation of mutations. By chance, these mutations could confer on cells mechanisms to subvert the PKR/eIF2a cell death pathway. Such malignant cells would survive a high expression of P-PKR and/or P-eIF2a, as exemplified by the CCA cells in this study. Such bypass mechanisms seem to be diverse. Herein, we have identified two distinct survival mechanisms: (1) the failure of eIF2a phosphorylation by P-PKR (M214 and M139) and (2) sustained global protein synthesis despite P-eIF2a (M156). At the molecular level, there may be myriads of such mechanisms, which await further study.
Regarding the modified PKR pathways that CCA cells have developed, several points should be discussed. First, the P-eIF2a branch ceased to function, but P-PKR and its NF-kB branch remained intact in all the CCA cells tested here. Although CCA cells were P-PKR þ , P-PKR was further induced by nc886 depletion Figure 6 . The intrinsic expression of P-eIF2a, which was independent of P-PKR, was bypassed by eIF2B overexpression in CCA cells. intrinsic expression of P-eIF2a. In any case, we have shown that one mechanism for CCA cells to tolerate P-eIF2a was overexpression of eIF2B ( Figure 6b) .
Collectively from our data obtained from CCA cells, we propose an updated tumor surveillance model. First, cells develop a mechanism (for example, eIF2B overexpression) by which they survive in spite of the classical P-eIF2a effects. Perhaps, this process is stochastic by random mutations. In any case, these cells are able to survive, even if nc886 is suppressed and thereby PKR is activated during tumorigenesis. Once these cells bypass the nc886/PKR/eIF2a action, they take advantage of P-PKR's oncogenic role by virtue of its ability to activate NF-kB. Consistently, along with others, we have shown that NF-kB activity is higher in CCA and required for CCA cell proliferation ( Figure 5 and Onori et al. 36 ). Given that nc886 1 and PKR (reviewed in Garcia et al. 7 ) are expressed ubiquitously, we expect that the tumor surveillance mechanism operates in a wide range of cancers besides CCA. We will expand our study from CCA to other types of cancer, such as breast, lung and head-and-neck cancers. 1 Beyond the in vitro twodimensional cell cultures that we used here, we will test our tumor surveillance model also in more in vivo contexts, such as threedimensional matrigel cultures or an animal model system. nc886/ PKR's in vivo contribution to cancer incident rates should be evaluated ultimately in an animal model, although a simple knockout mouse may not be feasible because nc886 does not seem to exist in mice. We are currently searching for an alternative animal model or a humanized mouse system.
MATERIALS AND METHODS
Cell lines, antibodies and other reagents MMNK1 cholangiocyte and CCA cells (summarized Table 1 ) were a kind gift from Dr Sopit Wongkham (Khon Kaen University, Khon Kaen, Thailand). Antibodies were obtained as follows: p58IPK, caspase-3 (cleaved), AIF (apoptosis-inducing factor), poly(ADP-ribose) polymerase (cleaved), eIF2B-e from Cell Signaling Technology (Danvers, MA, USA); MetAP2(p67) from Invitrogen (Carlsbad, CA, USA). All other antibodies were described in Lee et al. 1 Basic chemicals and reagents, including 2-AP, were purchased from Sigma-Aldrich (St Louis, MO, USA). CAPE was purchased from Tocris Bioscience (Minneapolis, MN, USA).
Plasmid DNAs, RNAs and transfection pNF-kB-Luc (Stratagene, La Jolla, CA, USA), pRL-SV40 (Promega, Madison, WI, USA) and pcDNA3.1-Zeo( þ )-Pp 1 were used for luciferase assays. siRNAs against PKR were Stealth RNAi siRNA (Invitrogen) whose sequences are available on request. Yeast tRNA was purchased from Applied Biosystems/Ambion (Carlsbad, CA, USA). Anti-oligos (against nc886 and vtRNA1-1), synthetic nc886 and poly(I:C)-LMW (0.2-1 kb) were purchased or prepared as described in Lee et al. Assays (measurement/analysis of RNA, luciferase assays and cell proliferation assays) All these assays were performed as previously described in Lee et al., In vitro kinase assay or measurement of nc886 following PKR immunoprecipitation PKR immunoprecipitation was performed as described in Ikegami et al., 47 except that all the buffers contained 80 units/ml of RNase inhibitor (New England Biolabs, Ipswich, MA, USA) and 1 mM Ribonucleoside Vanadyl Complex (New England Biolabs). Washed immunoprecipitates (bound to beads) were subjected to different further manipulations per experimental purposes. To test nc886 association with PKR (Figure 2c experiments) , the beads were resuspended with Trizol reagents (Invitrogen) for RNA isolation. During RNA isolation, 5 mg of yeast tRNA was added as a carrier for isopropanol precipitation. To measure in vitro kinase activity of PKR (Figure 2e, f and 5a experiments) , the beads were resuspended in 20 ml of kinase buffer 47 Electrophoretic mobility shift assay Synthetic nc886 for an EMSA template was prepared by in vitro transcription with [a-32 P]-CTP. Purified PKR was the N-terminal segment (amino-acid coordinates 1-184 of NP_002750.1) containing two dsRNAbinding domains (dsRBM1-2). dsRBM1-2 was overexpressed from pET-23a plasmid (Novagen, Gibbstown, NJ, USA) in E. coli and was purified on a Ni-NTA column (Qiagen, Valencia, CA, USA). Purified nc886 and dsRBM1-2 were mixed in 20 ml EMSA buffer (200 mM Tris pH7.4, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 40 units RNase inhibitor, 2.5 mg tRNA and 2 mg BSA) and incubated for 15 min on ice. The samples were resolved on a 10% nondenaturing polyacrylamide gel.
Protein synthesis assay
Subconfluent cells (B10 6 ) in a 6-cm dish were treated with 4 mCi of [ 35 S]-methionine in 2 ml of Dulbecco's modified Eagle's medium (without Lglutamine, L-methionine and L-cystine) containing dialyzed fetal bovine serum. After 1-h incubation, cells were harvested and lysed. Cell lysates were precipitated with 10% trichloroacetic acid, resuspended in 1 Â SDS-PAGE loading buffer and loaded onto a 10% SDS-polyacrylamide gel. The gel was stained with Coomassie brilliant blue, dried and visualized by autoradiography. Aliquots of lysates were also subjected to scintillation counting using Beckman LS 6500 Scintillation Counter (Beckman Coulter, Inc., Indianapolis, IN, USA) to quantify incorporated [ 
Clinical samples for qRT-PCR of nc886
The frozen liver tissues of 16 CCA patients admitted to Srinakarin Hospital (an affiliated hospital to Khon Kaen University) were obtained from the specimen bank of the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine (Khon Kaen University). Informed consent was obtained from each subject before surgery and the research protocol (#HE521209) was approved by the Human Research Ethics Committee (Khon Kaen University). Normal bile duct epithelia were examined and taken from non-cancerous portions of CCA liver tissues.
IHC analysis for P-PKR
Eight formalin-fixed, paraffin-embedded intrahepatic CCA samples with matched normal liver tissue samples were obtained from University of Texas, MD Anderson Cancer Center. All samples were prepared in one tissue microarray block and then cut in 5 mm thick sections. Using the rabbit antibody against P-PKR at Thr446 (Abcam, Cambridge, MA, USA), the immunostaining was performed by the avidin-biotin-peroxidase complex method. Antigen retrieval was performed by using citrate buffer (pH 6.0). The section was incubated with the primary antibody (1:50 dilution) for 45 min and biotinylated anti-rabbit immunoglobulin G for 30 min at room temperature. Finally, 3,3 0 -diaminobenzidine and Mayer's hematoxylin were used as a chromogen and counter staining, respectively. The P-PKR expression was interpreted by a pathologist.
